Down-regulation of ING4 is associated with initiation and progression of lung cancer

Histopathology

Volumn 57, Issue 2, 2010, Pages 271-281

  Wang, Qiu Shi ^a   Li, Ming ^a   Zhang, Lin You ^a   Jin, Yan ^a   Tong, Dan Dan ^a   Yu, Yang ^a   Bai, Jing ^a   Huang, Qi ^a   Liu, Fang Li ^a   Liu, An ^a   Lee, Ki Young ^b   Fu, Song Bin ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALGARY   (Canada)

^c Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

Author keywords

ING4 expression; lung cancer; mRNA; tumour suppressor gene

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH INHIBITOR; INHIBITOR OF GROWTH FAMILY 4; UNCLASSIFIED DRUG;

ADENOSQUAMOUS CARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOID; CELL CYCLE ARREST; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DNA REPAIR; DOWN REGULATION; FEMALE; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INHIBITOR OF GROWTH FAMILY 4 GENE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL CELL CARCINOMA; STOMACH ADENOCARCINOMA; TRANSCRIPTION REGULATION; TUMOR CELL; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

AGED; BASE SEQUENCE; BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL NUCLEUS; CYTOPLASM; DISEASE PROGRESSION; DNA PRIMERS; DOWN-REGULATION; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77955834791     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03623.x     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 74 108.
2. Ishibashi H, Suzuki T, Suzuki S et al. Progesterone receptor in nonα-SMAll cell lung cancer - a potent prognostic factor and possible target for endocrine therapy. Cancer Res. 2005 65 6450 6458.
3. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol. Biomarkers Prev. 2005 14 243 250.
4. Garkavtsev I, Kazarov A, Gudkov A, Riabowol K. Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat. Genet. 1996 14 415 420.
5. Shiseki M, Nagashima M, Pedeux RM et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003 63 2373 2378.
6. Nagashima M, Shiseki M, Miura K et al. DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53. Proc. Natl Acad. Sci. USA 2001 98 9671 9676.
7. Nagashima M, Shiseki M, Pedeux RM et al. A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene 2003 22 343 350.
8. Gong W, Suzuki K, Russell M, Riabowol K. Function of the ING family of PHD proteins in cancer. Int. J. Biochem. Cell Biol. 2005 37 1054 1065. (Pubitemid 40311746)
9. Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. The new tumour suppressor genes ING: genomic structure and status in cancer. Int. J. Cancer 2008 123 1483 1490.
10. Soliman MA, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem. Sci. 2007 32 509 519.
11. Kameyama K, Huang CL, Liu D et al. Reduced ING1b gene expression plays an important role in carcinogenesis of nonα-SMAll cell lung cancer patients. Clin. Cancer Res. 2003 9 4926 4934.
12. Nouman GS, Anderson JJ, Mathers ME et al. Nuclear to cytoplasmic compartment shift of the p33ING1b tumour suppressor protein is associated with malignancy in melanocytic lesions. Histopathology 2002 40 360 366.
13. Okano T, Gemma A, Hosoya Y et al. Alterations in novel candidate tumour suppressor genes, ING1 and ING2 in human lung cancer. Oncol. Rep. 2006 15 545 549.
14. Gunduz M, Beder LB, Gunduz E et al. Downregulation of ING3 mRNA expression predicts poor prognosis in head and neck cancer. Cancer Sci. 2008 99 531 538.
15. Zhang X, Wang KS, Wang ZQ et al. Nuclear localization signal of ING4 plays a key role in its binding to p53. Biochem. Biophys. Res. Commun. 2005 331 1032 1038.
16. Ozer A, Bruick RK. Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumour suppressor protein ING4. Cell Cycle 2005 4 1153 1156.
17. Ozer A, Wu LC, Bruick RK. The candidate tumour suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc. Natl Acad. Sci. USA 2005 102 7481 7486.
18. Garkavtsev I, Kozin SV, Chernova O et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004 428 328 332.
19. Kim S, Chin K, Gray JW, Bishop JM. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumour suppressor gene in human cancer. Proc. Natl Acad. Sci. USA 2004 101 16251 16256.
20. Nagahama Y, Ishimaru M, Osaki M et al. Apoptotic pathway induced by transduction of RUNX3 in the human gastric carcinoma cell line MKN-1. Cancer Sci. 2008 99 23 30.
21. Xie Y, Zhang H, Sheng W, Xiang J, Ye Z, Yang J. Adenovirus-mediated ING4 expression suppresses lung carcinoma cell growth via induction of cell cycle alteration and apoptosis and inhibition of tumour invasion and angiogenesis. Cancer Lett. 2008 271 105 116.
22. Gunduz M, Nagatsuka H, Demircan K et al. Frequent deletion and down-regulation of ING4, a candidate tumour suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene 2005 356 109 117.
23. Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 2008 29 1373 1379.
24. Li M, Jin Y, Sun WJ et al. Reduced expression and novel splice variants of ING4 in human gastric adenocarcinoma. J. Pathol. 2009 219 87 95.
25. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart.
26. Greene FL, Page DL, Fleming ID et al. eds. AJCC cancer staging manual, 6th edn.
27. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987 8 138 140.
28. Russell M, Berardi P, Gong W, Riabowol K. Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp. Cell Res. 2006 312 951 961.
29. Nozell S, Laver T, Moseley D et al. The ING4 tumor suppressor attenuates NF-kappaB activity at the promoters of target genes. Mol. Cell. Biol. 2008 28 6632 6645.
30. Tzouvelekis A, Aidinis V, Harokopos V et al. Down-regulation of the inhibitor of growth family member 4 (ING4) in different forms of pulmonary fibrosis. Respir. Res. 2009 10 14.
31. Unoki M, Shen JC, Zheng ZM, Harris CC. Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J. Biol. Chem. 2006 281 34677 34686.
32. Shen JC, Unoki M, Ythier D et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 2007 67 2552 2558.
33. Raho G, Miranda C, Tamborini E, Pierotti MA, Greco A. Detection of novel mRNA splice variants of human ING4 tumour suppressor gene. Oncogene 2007 26 5247 5257.
34. Tsai KW, Tseng HC, Lin WC. Two wobble-splicing events affect ING4 protein subnuclear localization and degradation. Exp. Cell Res. 2008 314 3130 3141.
35. Wang Y, Dai DL, Martinka M, Li G. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma. Clin. Cancer Res. 2007 13 4111 4116.
36. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin. Oncol. 2001 28 3 13.